AU8778498A - Nicotine antagonists for nicotine-responsive neuropsychiatric disorders - Google Patents

Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Info

Publication number
AU8778498A
AU8778498A AU87784/98A AU8778498A AU8778498A AU 8778498 A AU8778498 A AU 8778498A AU 87784/98 A AU87784/98 A AU 87784/98A AU 8778498 A AU8778498 A AU 8778498A AU 8778498 A AU8778498 A AU 8778498A
Authority
AU
Australia
Prior art keywords
nicotine
antagonists
neuropsychiatric disorders
responsive
responsive neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU87784/98A
Other languages
English (en)
Inventor
Paul Ronald Sanberg
Roland Douglas Shytle
Archie Aaron Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida Research Foundation Inc
Original Assignee
University of South Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/020689 external-priority patent/WO1999007356A1/en
Application filed by University of South Florida Research Foundation Inc filed Critical University of South Florida Research Foundation Inc
Publication of AU8778498A publication Critical patent/AU8778498A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AU87784/98A 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders Abandoned AU8778498A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5523497P 1997-08-11 1997-08-11
US60055234 1997-08-11
US93536497A 1997-09-22 1997-09-22
US08935364 1997-09-22
WOUS9720689 1997-11-07
PCT/US1997/020689 WO1999007356A1 (en) 1997-08-11 1997-11-07 Nicotine antagonists for neuropsychiatric disorders
PCT/US1998/016634 WO1999007378A1 (en) 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
AU8778498A true AU8778498A (en) 1999-03-01

Family

ID=27368798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87784/98A Abandoned AU8778498A (en) 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Country Status (6)

Country Link
JP (1) JP4640888B2 (ja)
AU (1) AU8778498A (ja)
CA (1) CA2300148C (ja)
DK (1) DK1011678T3 (ja)
ES (1) ES2299214T3 (ja)
WO (1) WO1999007378A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103781A3 (en) * 1998-10-16 2003-09-29 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
US11766429B1 (en) 2020-08-26 2023-09-26 University Of South Florida Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
JP2003524573A (ja) 2003-08-19
ES2299214T3 (es) 2008-05-16
CA2300148A1 (en) 1999-02-18
JP4640888B2 (ja) 2011-03-02
DK1011678T3 (da) 2008-05-05
CA2300148C (en) 2009-06-23
WO1999007378A1 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
AU3579897A (en) Fibrinogen receptor antagonists
AU2143295A (en) Neurokinin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
AU7692996A (en) Receptor antagonists
AU3953795A (en) Bicyclic neuropeptide y receptor antagonists
AU2524995A (en) Neurokinine (tachykinine) antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
AU3899997A (en) Muscarinic antagonists
AU1765695A (en) Non-peptidyl tachykinin receptor antagonists
AU4746297A (en) Vitronectin receptor antagonists
IL123581A0 (en) Pyrimidine derivatives as 5HT2c- receptor antagonists
AU2242197A (en) Benzimidzolyl neuropeptide y receptor antagonists
HU9600663D0 (en) Endothelin-receptor antagonists
EP0885205A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
EP0885213A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
AU1558899A (en) Isoquinoline derivatives for use against cns disorders
EP0796098A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
AU1230795A (en) Adhesion receptor antagonists
AU6856796A (en) Des-arg9-bk antagonists
EP0801650A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
AU9185598A (en) Novel neuropeptide y receptor antagonists
AU3661895A (en) Adhesion receptor antagonists
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
EP0794779A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
AU8778498A (en) Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase